Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young Hoon | - |
dc.contributor.author | Kim, Jee Yeon | - |
dc.contributor.author | Kim, Dong Hyun | - |
dc.contributor.author | Ko, Youngmin | - |
dc.contributor.author | CHOI, JI YOON | - |
dc.contributor.author | Shin, Sung | - |
dc.contributor.author | Jung, Joo Hee | - |
dc.contributor.author | Park, Su-Kil | - |
dc.contributor.author | Kim, Sung-Han | - |
dc.contributor.author | Kwon, Hyunwook | - |
dc.contributor.author | Han, Duck, Jong | - |
dc.date.accessioned | 2023-09-18T06:44:28Z | - |
dc.date.available | 2023-09-18T06:44:28Z | - |
dc.date.created | 2023-07-19 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 14712369 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/190728 | - |
dc.description.abstract | Background Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving perioperative treatment with rituximab, which is associated with prolonged B-cell depletion and possible risk of PCP occurrence; however, the optimal prophylaxis duration according to rituximab treatment is yet unknown. We compared the occurrence of PCP and the duration of prophylaxis in KT recipients according to rituximab treatment. Methods We retrospectively analyzed 2110 patients who underwent KT between January 2009 and December 2016, who were divided into non-Rituximab group (n = 1588, 75.3%) and rituximab group (n = 522, 24.7%). Results In the rituximab group, the estimated number needed to treat (NNT) for prophylaxis prolongation from 6 to 12 months was 29.0 with a relative risk reduction of 90.0%. In the non-rituximab group, the estimated NNT value was 133.3 and the relative risk reduction was 66.4%. Rituximab treatment (hazard ratio (HR) = 3.09; P < 0.01) and acute rejection (HR = 2.19; P = 0.03) were significant risk factors for PCP in multivariate analysis. Conclusions Our results suggest that maintaining PCP prophylaxis for 12 months may be beneficial in KT recipients treated with rituximab for desensitization or acute rejection treatment. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.title | Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | CHOI, JI YOON | - |
dc.identifier.doi | 10.1186/s12882-020-01750-8 | - |
dc.identifier.scopusid | 2-s2.0-85081700995 | - |
dc.identifier.wosid | 000519923500002 | - |
dc.identifier.bibliographicCitation | BMC NEPHROLOGY, v.21, no.1, pp.1 - 9 | - |
dc.relation.isPartOf | BMC NEPHROLOGY | - |
dc.citation.title | BMC NEPHROLOGY | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | RISK-FACTORSB-CELLS | - |
dc.subject.keywordAuthor | Kidney transplantationRituximabPneumocystis | - |
dc.identifier.url | https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-01750-8 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.